DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects

Information source: Nastech Pharmaceutical Company, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Obesity

Intervention: Nasal Placebo (Drug); Placebo Capsule (Drug); PYY3-36 (Drug); PYY3-36 (Drug); PYY3-36 (Drug); Sibutramine (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Nastech Pharmaceutical Company, Inc.

Official(s) and/or principal investigator(s):
Gordon Brandt, M.D., Study Director, Affiliation: Nastech Pharmaceutical Company, Inc.

Summary

The purpose of this study is to determine the effect of nasal PYY3-36 on weight loss post 24 weeks of treatment.

Clinical Details

Official title: A 24-Week, Blinded, Randomized, Placebo-Controlled Dose-Ranging Trial of Nasal PYY3-36 for Weight Loss in Healthy Obese Patients

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: To evaluate the effect of increasing nasal PYY3 36 dosing on weight loss post 24 weeks of treatment

Secondary outcome: To evaluate the safety of three nasal PYY3 36 dose groups compared to nasal placebo

Detailed description: This is a multi-center, Phase 2 double-blind, randomized, placebo-controlled trial in healthy obese patients. The primary objective of the study is to evaluate the effect of increasing nasal PYY3-36 dosing on weight loss post 24 weeks of treatment. Secondary Objectives:

- To evaluate the safety of three nasal PYY3 36 dose groups compared to nasal placebo

- To compare the weight loss post 12 and 24 weeks of treatment for each of the three

nasal PYY3 36 dose groups versus the nasal placebo group

- To compare the proportion of patients who lose at least 5% and 10% of the baseline body

weight post 12 and 24 weeks of therapy for each of the three nasal PYY3 36 dose groups versus the nasal placebo group

- To compare the weight loss and proportion of patients who lose at least 5% of the

baseline body weight post 12 and 24 weeks of treatment with sibutramine versus capsule placebo

- To compare the weight loss and proportion of patients who lose at least 5% of the

baseline body weight post 12 and 24 weeks of treatment with nasal placebo versus capsule placebo

- To compare the weight loss and proportion of patients who lose at least 5% of the

baseline body weight post 12 and 24 weeks of treatment with sibutramine versus the nasal PYY3 36 dose groups

- To evaluate the effect of 12 and 24 weeks of treatment with nasal PYY3 36 and

sibutramine on fasting lipid profile, plasma glucose, insulin, blood pressure and pulse, waist circumference and BMI

- To evaluate the effect of 24 weeks of treatment with nasal PYY3 36 and sibutramine on

HbA1c levels

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or Female patients 18 and 65 years, inclusive;

- BMI 30-43 kg/m2, inclusive;

- In good health, determined by medical history and physical examination, as well as

normal 12-lead ECG and vital signs;

- Non-smoker and no use of tobacco or nicotine products for at least 3 months;

- Females will be non-pregnant, non-lactating, and either post-menopausal for at least

1 year, surgically sterile (including tubal ligation, hysterectomy) for at least 3 months, until 30 days following Study Completion be willing to use an approved method of contraception;

- Has normal nasal mucosa.

Exclusion Criteria:

- Previous surgical treatment for obesity;

- Serious Medical Condition

- Serious Psychiatric illness

- Organic causes of obesity (e. g. untreated hypothyroidism)

- Type 1 or Type 2 Diabetes;

- Presence of uncontrolled hypertension

- On prohibited concomitant medication

Locations and Contacts

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Peoria, Arizona 85381, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Phoenix, Arizona 85050, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Anaheim, California 92801, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Beverly Hills, California 90211, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Carmichael, California 95608, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Orange, California 92869, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Sacramento, California 95816, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, San Diego, California 92130, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, San Diego, California 92108, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, San Francisco, California 94102, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Pembroke Pines, Florida 33024, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Atlanta, Georgia 30328, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Augusta, Georgia 30909, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Evansville, Indiana 47713, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Valparaiso, Indiana 46383, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Baton Rouge, Louisiana 70808, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Brooklyn Center, Minnesota 55430, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Las Vegas, Nevada 89104, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Manlius, New York 13104, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Charlotte, North Carolina 28209, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Raleigh, North Carolina 27612, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Cleveland, Ohio 44122, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Reading, Pennsylvania 19606, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Greer, South Carolina 29651, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Mt. Pleasant, South Carolina 29464, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Austin, Texas 78705, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, San Antonio, Texas 78229-3894, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Temple, Texas 76508, United States

For additional information regarding investigative sites for this trial, contact 1-425-415-3011, Salt Lake City, Utah 84049, United States

Additional Information

Starting date: October 2007
Last updated: September 12, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017